{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-114206","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.287042+00:00","generated_at":"2026-06-22T08:24:50.748963+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Cara Therapeutics appoints Lisa von Moltke, M.D. to Board of Directors","bullets":["Dr. von Moltke is EVP and Chief Medical Officer at Seres Therapeutics, with prior roles at Alkermes and Sanofi.","She will receive $45K annual cash retainer, $5K for nominating committee, and initial option grant of $350K vesting quarterly over 3 years.","Appointment effective November 1, 2022; term expires at 2023 Annual Meeting; she will serve on nominating and corporate governance committee.","Her expertise is expected to support execution of strategy for oral difelikefalin in pruritus, a key pipeline program."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-114206","json":"https://secwatch.observer/filing/0001104659-22-114206.json","markdown":"https://secwatch.observer/filing/0001104659-22-114206.md","text":"https://secwatch.observer/filing/0001104659-22-114206.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465922114206/0001104659-22-114206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465922114206/tm2229601d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:24:50.748963+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20d65cf526","claim":"Lisa von Moltke, M.D. was appointed as Director at Tvardi Therapeutics, Inc..","evidence_excerpt":"On November 1, 2022, the Board of Directors (the “Board”) of Cara Therapeutics, Inc. (the “Company”) appointed Lisa von Moltke, M.D. to serve as a member of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465922114206/0001104659-22-114206-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}